<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868437</url>
  </required_header>
  <id_info>
    <org_study_id>ODural</org_study_id>
    <nct_id>NCT02868437</nct_id>
  </id_info>
  <brief_title>Effectiveness of Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion</brief_title>
  <official_title>Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bilar Medikal, Turkey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, controlled study evaluates the efficacy of self-crosslinked
      hyaluronic acid gel to prevent the development of de-novo intrauterine adhesions following
      curettage for retained product after second trimester abortion. One group of participants
      will underwent curettage plus intrauterine application of self-crosslinked hyaluronic acid
      gel while the other group will underwent curettage alone (control group).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrauterine adhesions are the major long‐term complication of curettage for retained
      products of conception. The risk of adhesion is higher after second trimester abortion. This
      complication may result in infertility, recurrent miscarriages and irregular periods with
      dysmenorrhea and pelvic pain.

      They have been reported that the intrauterine application of auto‐crosslinked hyaluronic acid
      gel following hysteroscopic adhesiolysis or hysteroscopic surgery significantly reduces the
      formation of post‐operative intrauterine adhesions.

      The aim of this prospective, randomized, controlled study is to evaluate the efficacy of
      self-crosslinked hyaluronic acid gel in the reduction of development of de‐novo
      post‐curettage adhesions at 2 months follow‐up.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of de‐novo post‐curettage adhesions</measure>
    <time_frame>2 months</time_frame>
    <description>In 2 months following the curettage, Hysteroscopy will perform to observe of whether there is any intrauterine adhesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The characteristic of the intrauterine adhesions</measure>
    <time_frame>2 months</time_frame>
    <description>If any intrauterine adhesion is detected during the Hysteroscopy, American Fertility Society/American Society for Reproductive Medicine classification of intrauterine adhesions will be used to describe to the characteristic of the intrauterine adhesions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Placenta Retained</condition>
  <condition>Uterine Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients who are having curettage for retained product after second trimester abortion will receive no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intrauterine self-cross-linked hyaluronic acid gel</intervention_name>
    <description>intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has curettage for retained product after second trimester abortion

        Exclusion Criteria:

          -  History of curettage or other intrauterine surgery

          -  History of post-abortion complication or infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ozlem Dural, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University School Of Medicine, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sultan Can, M.D.</last_name>
    <phone>+90 212 4142000</phone>
    <phone_ext>31687</phone_ext>
    <email>sltncn89@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gamze Yilmaz, M.D.</last_name>
    <phone>+90 212 4142000</phone>
    <email>gmzylmz89@gmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Hooker AB, Lemmers M, Thurkow AL, Heymans MW, Opmeer BC, Brölmann HA, Mol BW, Huirne JA. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update. 2014 Mar-Apr;20(2):262-78. doi: 10.1093/humupd/dmt045. Epub 2013 Sep 29. Review.</citation>
    <PMID>24082042</PMID>
  </results_reference>
  <results_reference>
    <citation>Guida M, Acunzo G, Di Spiezio Sardo A, Bifulco G, Piccoli R, Pellicano M, Cerrota G, Cirillo D, Nappi C. Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Hum Reprod. 2004 Jun;19(6):1461-4. Epub 2004 Apr 22.</citation>
    <PMID>15105384</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 14, 2016</last_update_submitted>
  <last_update_submitted_qc>August 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Ozlem Dural</investigator_full_name>
    <investigator_title>M.D., Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Diseases</mesh_term>
    <mesh_term>Placenta, Retained</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

